Alzamend Neuro (NASDAQ:ALZN – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.07), Zacks reports.
Alzamend Neuro Stock Performance
Alzamend Neuro stock traded up $0.03 during midday trading on Wednesday, hitting $1.35. 70,780 shares of the company’s stock were exchanged, compared to its average volume of 138,688. Alzamend Neuro has a 12 month low of $0.84 and a 12 month high of $3.14. The company has a market cap of $5.14 million, a PE ratio of -0.62 and a beta of 0.14. The firm has a 50-day moving average of $1.18 and a two-hundred day moving average of $1.52.
Wall Street Analyst Weigh In
Separately, Weiss Ratings downgraded Alzamend Neuro from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Alzamend Neuro presently has an average rating of “Hold” and a consensus target price of $28.00.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Alzamend Neuro stock. Geode Capital Management LLC increased its position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) by 33.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,506 shares of the company’s stock after acquiring an additional 6,928 shares during the quarter. Geode Capital Management LLC owned about 0.72% of Alzamend Neuro worth $50,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 49.61% of the company’s stock.
About Alzamend Neuro
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Recommended Stories
- Five stocks we like better than Alzamend Neuro
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
